IMARA Inc. (NASDAQ:IMRA) Short Interest Update

IMARA Inc. (NASDAQ:IMRA – Get Rating) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 265,800 shares, an increase of 187.4% from the April 15th total of 92,500 shares. Based on an average daily trading volume, of 408,700 shares, the short-interest ratio is currently 0.7 days. Currently, 1.8% of the company’s stock are short sold.

In related news, Director David M. Mott bought 50,398 shares of the business’s stock in a transaction on Friday, February 18th. The shares were bought at an average price of $1.30 per share, for a total transaction of $65,517.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David M. Mott bought 65,817 shares of the business’s stock in a transaction on Tuesday, February 22nd. The stock was bought at an average price of $1.56 per share, for a total transaction of $102,674.52. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 688,494 shares of company stock worth $965,157. Insiders own 39.60% of the company’s stock.

A number of large investors have recently made changes to their positions in IMRA. Cubist Systematic Strategies LLC acquired a new position in IMARA in the third quarter valued at approximately $49,000. Bank of New York Mellon Corp purchased a new stake in shares of IMARA in the third quarter valued at approximately $76,000. Trexquant Investment LP purchased a new stake in shares of IMARA in the third quarter valued at approximately $80,000. Goldman Sachs Group Inc. increased its position in shares of IMARA by 260.0% in the third quarter. Goldman Sachs Group Inc. now owns 37,962 shares of the company’s stock valued at $155,000 after buying an additional 27,416 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in shares of IMARA by 35.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 83,866 shares of the company’s stock valued at $189,000 after buying an additional 21,875 shares in the last quarter. 71.07% of the stock is owned by institutional investors.

A number of equities research analysts have recently weighed in on IMRA shares. Citigroup lowered IMARA from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 5th. Zacks Investment Research raised IMARA from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Friday, March 18th. Finally, SVB Leerink reaffirmed a “market perform” rating on shares of IMARA in a report on Wednesday, April 6th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $11.75.

NASDAQ:IMRA traded up $0.19 during trading hours on Friday, reaching $1.29. The company had a trading volume of 1,530 shares, compared to its average volume of 339,855. IMARA has a 1-year low of $0.97 and a 1-year high of $9.29. The firm has a market cap of $33.90 million, a PE ratio of -0.46 and a beta of 2.60. The business’s 50 day moving average price is $1.47 and its 200-day moving average price is $2.06.

IMARA (NASDAQ:IMRA – Get Rating) last announced its quarterly earnings results on Tuesday, March 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.26. During the same period last year, the company earned ($1.09) earnings per share. On average, equities analysts anticipate that IMARA will post -2.09 earnings per share for the current year.

IMARA Company Profile (Get Rating)

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia.

Read More